ONO 3403, a synthetic serine protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-α and nitric oxide production and protects mice from lethal endotoxic shock

Innate Immunity

Volumn 17, Issue 1, 2010, Pages 97-105

  Tumurkhuu, Gantsetseg ^a   Koide, Naoki ^a   Hiwasa, Takaki ^b   Ookoshi, Motohiro ^c   Dagvadorj, Jargalsaikhan ^a   Abu Shadat Mohammod Noman, ^a   Iftakhar E Khuda, Imtiaz ^a   Naiki, Yoshikazu ^a   Komatsu, Takayuki ^a   Yoshida, Tomoaki ^a   Yokochi, Takashi ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c Showagakuin Junior College   (Japan)

Author keywords

endotoxic shock; LPS; NO; ONO 3403; synthetic serine protease inhibitor; TNF

Indexed keywords

BETA INTERFERON; CAMOSTAT MESILATE; GALACTOSAMINE; I KAPPA B ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON REGULATORY FACTOR 3; LIPOPOLYSACCHARIDE; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; NITRIC OXIDE; ONO 3403; SERINE PROTEINASE INHIBITOR; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HISTOPATHOLOGY; LIVER INJURY; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SEPTIC SHOCK; SIGNAL TRANSDUCTION;

ALLYLGLYCINE; ANIMALS; BENZAMIDINES; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; FEMALE; GABEXATE; GENE EXPRESSION; I-KAPPA B PROTEINS; INTERFERON REGULATORY FACTOR-3; INTERFERON-GAMMA; INTERLEUKIN-6; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIPOPOLYSACCHARIDES; LIVER; MACROPHAGES; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; MYELOID DIFFERENTIATION FACTOR 88; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PHOSPHORYLATION; SERINE PROTEASES; SERINE PROTEINASE INHIBITORS; SHOCK, SEPTIC; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 79951801117     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425909353641     Document Type: Article

References (40)

1. Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 2006 ; 5: 785-799. (Pubitemid 44323703)
2. Tamura Y., Hirado M., Okamura K. et al. Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r, and C1 esterase. Biochim Biophys Acta 1997 ; 484: 417-422.
3. Griscavage JM, Wilk S., Ignarro LJ Serine and cysteine proteinase inhibitors prevent nitric oxide production by activated macrophages by interfering with transcription of the inducible NO synthase gene. Biochem Biophys Res Commun 1995 ; 215: 721-729.
4. Aosasa S., Ono S., Mochizuki H., Tsujimoto H., Ueno C., Matsumoto A. Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor alpha production of monocytes. Shock 2001 ; 15: 101-105. (Pubitemid 33598169)
5. Kanoh M., Ibata H., Miyagawa M. et al. Clinical effects of camostat in chronic pancreatitis. Biomed Res 1989 ; 10: 145-150. (Pubitemid 20019208)
6. Hsu JT, Chen HM, Chiu DF et al. Efficacy of gabexate mesilate on disseminated intravascular coagulation as a complication of infection developing after abdominal surgery. J Formos Med Assoc 2004 ; 103: 678-684.
7. Ohkoshi M., Sasaki Y. Antimetastatic activity of a synthetic serine protease inhibitor, FOY-305 (Foypan). In Vivo 2005 ; 19: 133-136. (Pubitemid 40450387)
8. Ikeda T., Murakami K., Hayakawa Y. et al. Anti-invasive activity of synthetic serine protease inhibitors and its combined effect with a matrix metalloproteinase inhibitor. Anticancer Res 1998 ; 18: 4259-4265. (Pubitemid 29043643)
9. Senokuchi K., Nakai H., Nakayama Y. et al. New orally active serine protease inhibitors. J Med Chem 1995 ; 38: 2521-2523.
10. Ohkoshi M., Denda T., Hiwasa T. Growth-suppressive activity of a serine protease inhibitors, FOY 305, ONO-3403 and FO-349 toward human carcinoma cells. Oncol Rep 1997 ; 4: 521-523. (Pubitemid 27210189)
11. Pålsson-McDermott EM, O'Neill LA Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology 2004 ; 113: 153-162. (Pubitemid 39312442)
12. Freudenberg MA, Tchaptchet S., Keck S. et al. Lipopolysaccharide sensing an important factor in the innate immune response to Gram-negative bacterial infections: benefits and hazards of LPS hypersensitivity. Immunobiology 2008 ; 213: 193-203.
13. Lin WJ, Yeh WC Implication of Toll-like receptor and tumor necrosis factor alpha signaling in septic shock. Shock 2005 ; 24: 206-229.
14. Takeda K., Kaisho T., Akira S. Toll-like receptors. Annu Rev Immunol 2003 ; 21: 335-376. (Pubitemid 37174535)
15. Akira S., Takeda K. Toll-like receptor signaling. Nat Rev Immunol 2004 ; 4: 499-511.
16. Murakami K., Okajima K., Uchiba M., Okabe K., Takatsuki K. Gabexate mesilate, a synthetic protease inhibitor, attenuates endotoxin-induced pulmonary vascular injury by inhibiting tumor necrosis factor production by monocytes. Crit Care Med 1996 ; 24: 1047-1053.
17. Inoue K., Takano H., Shimada A. et al. Urinary trypsin inhibitor protects against systemic inflammation induced by lipopolysaccharide. Mol Pharmacol 2005 ; 67: 673-680. (Pubitemid 40365315)
18. Takano H., Inoue K., Shimada A., Sato H., Yanagisawa R., Yoshikawa T. Urinary trypsin inhibitor protects against liver injury and coagulation pathway dysregulation induced by lipopolysaccharide/D-galactosamine in mice. Lab Invest 2009 ; 89: 833-839.
19. Yuksel M., Okajima K., Uchiba M. et al. Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-α production by inhibiting activation of both nuclear factor-?B and activator protein-1 in human monocytes. J Pharmacol Exp Ther 2003 ; 305: 298-305. (Pubitemid 36373864)
20. Iwadou H., Morimoto Y., Iwagaki H. et al. Differential cytokine response in host defence mechanisms triggered by Gram-negative and Gram-positive bacteria, and the roles of gabexate mesilate, a synthetic protease inhibitor. J Int Med Res 2002 ; 30: 99-108. (Pubitemid 34467438)
21. Nakamura A., Mori Y., Hagiwara K. et al. Increased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)-deficient mice. J Exp Med 2003 ; 197: 669-674. (Pubitemid 36314661)
22. Green LC, Wagner DA, Glowgowski J., Skepper PL, Wishnok JS, Tannenbaum SR Analysis of nitrate, nitrite and 15 N nitrate in biological fluids. Anal Biochem 1982 ; 126: 131-138. (Pubitemid 13203451)
23. Lu YC, Yeh WC, Ohashi PS LPS/TLR4 signal transduction pathway. Cytokine 2008 ; 42: 145-151.
24. Beutler B. Inferences, questions and possibilities in Toll-like receptor signaling. Nature 2004 ; 430: 257-263. (Pubitemid 38902439)
25. Mansell A., Reinicke A., Worrall DM, O'Neill LA The serine protease inhibitor antithrombin III inhibits LPS-mediated NF-kappaB activation by TLR-4. FEBS Lett 2001 ; 508: 313-317. (Pubitemid 33135461)
26. Lakhani SA, Bogue CW Toll-like receptor signaling in sepsis. Curr Opin Pediatr 2003 ; 15: 278-282. (Pubitemid 36578077)
27. Lin WJ, Yeh WC Implication of Toll-like receptor and tumor necrosis factor alpha signaling in septic shock. Shock 2005 ; 24: 206-209.
28. Hiwasa T., Shimada H., Ochiai T. et al. Decrease in growth factor receptors after treatment with serine protease inhibitor ONO-3403. Int J Oncol 2002 ; 20: 797-802.
29. Hiwasa T. Induction of apoptosis by a calpain stimulator, ONO 3403. Apoptosis 1996 ; 1: 75-80. (Pubitemid 126712779)
30. Yuksel M., Okajima K., Uchiba M., Okabe H. Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappaB and activator protein-1 in human monocytes. J Pharmacol Exp Ther 2003 ; 305: 298-305. (Pubitemid 36373864)
31. Dowling D., Hamilton CM, O'Neill SM A comparative analysis of cytokine responses, cell surface marker expression and MAPKs in DCs matured with LPS compared with a panel of TLR ligands. Cytokine 2008 ; 41: 254-262.
32. Morikawa A., Kato Y., Sugiyama T. et al. Role of nitric oxide in lipopolysaccharide-induced hepatic injury in D-galactosamine sensitized mice as an experimental endotoxic shock model. Infect Immun 1999 ; 67: 1018-1024. (Pubitemid 29108472)
33. Hayakawa M., Sawamura A., Yanagida Y., Sugano M., Hoshino H., Gando S. The response of antithrombin III activity after supplementation decreases in proportion to the severity of sepsis and liver dysfunction. Shock 2008 ; 30: 649-652.
34. Novelli GP, Innocenti P., Livi P. Gabexate mesilate (FOY), a new synthetic protease inhibitor, in the treatment of shock. An Italian multicenter study. Minerva Anesthesiol 1993 ; 59: 247-253.
35. Vanaman TC, Bradshaw RA Proteases in cellular regulation. J Biol Chem 1999 ; 274: 20047-20048.
36. Ward JR, Dower SK, Whyte MK, Buttle DJ, Sabroe I. Potentiation of TLR4 signaling by plasmin activity. Biochem Biophys Res Commun 2006 ; 341: 299-303. (Pubitemid 43152105)
37. Triantafilou M., Triantafilou K. The dynamics of LPS recognition: complex orchestration of multiple receptors. J Endotoxin Res 2005 ; 11: 5-11. (Pubitemid 40533073)
38. Morisato D., Anderson KV The Spatzle gene encodes a component of the extracellular signaling pathway establishing the dorsal-ventral pattern of the Drosophila embryo. Cell 1994 ; 76: 677-688.
39. Schneider DS, Jin Y., Morisato D., Anderson KV A processed form of the Spatzle protein defines dorsal ventral polarity in the Drosophila embryo. Development 1994 ; 120: 1243-1250.
40. Imler JL, Hoffmann JA Toll and Toll-like proteins: an ancient family of receptors signaling infection. Rev Immunogenet 1990 ; 2: 294-304.